tiprankstipranks
Sinovac Biotech (SVA)
NASDAQ:SVA
US Market

Sinovac Biotech (SVA) Income Statement

113 Followers

Sinovac Biotech Income Statement

Last quarter (Q4 2023), Sinovac Biotech's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Sinovac Biotech's net income was $―. See Sinovac Biotech’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-$ 448.27M$ 1.49B$ 19.37B$ 510.62M$ 246.05M
Cost of Revenue
-$ 181.52M$ -684.46M$ -1.07B$ 67.18M$ 32.47M
Gross Profit
-$ 266.75M$ 808.30M$ 18.30B$ 443.44M$ 213.58M
Operating Expense
-$ 813.48M$ -1.27B$ -749.43M$ 227.64M$ 144.73M
Operating Income
-$ -546.72M$ -460.85M$ 17.55B$ 215.81M$ 68.86M
Net Non Operating Interest Income Expense
-$ 82.85M$ 189.55M$ 99.73M$ 477.00K$ 1.35M
Other Income Expense
-$ -310.84M$ -296.54M$ 90.92M$ 333.00K$ 618.00K
Pretax Income
-$ -153.03M$ 25.24M$ 17.56B$ 216.62M$ 70.82M
Tax Provision
-$ 105.32M$ -62.89M$ 3.10B$ 31.44M$ 5.61M
Earnings From Equity Interest Net Of Tax
--$ 392.43M---
Net Income Common Stockholders
-$ -105.90M$ 107.88M$ 8.46B$ 104.35M$ 39.80M
Basic EPS
-$ -1.06$ 1.08$ 85.20$ 1.06$ 0.42
Diluted EPS
-$ -1.06$ 1.00$ 74.27$ 0.97$ 0.41
Basic Average Shares
-$ 99.61M$ 99.50M$ 99.31M$ 98.90M$ 94.88M
Diluted Average Shares
-$ 99.61M$ 114.17M$ 114.01M$ 113.66M$ 109.69M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
----$ 1.03$ 0.43
Rent Expense Supplemental
----$ 798.00K$ 811.00K
Total Expenses
-$ 994.99M$ -1.96B$ -1.82B$ 294.82M$ 177.20M
Net Income From Continuing And Discontinued Operation
-$ -99.92M$ 113.87M$ 8.47B$ 110.37M$ 44.93M
Normalized Income
-$ -33.76M--$ 110.51M$ 45.20M
Interest Expense
----$ 1.45M$ 650.00K
EBIT
-$ -150.77M$ 23.62M$ 17.46B$ 218.07M$ 71.47M
EBITDA
-$ -6.03M$ 180.22M$ 17.55B$ 222.11M$ 76.29M
Currency in USD

Sinovac Biotech Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis